ArticleCost effectiveness and resource allocation : C/E2026
Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants.
Article in Cost effectiveness and resource allocation : C/E, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe International Risk Scoring Tool (IRST) comprises three risk factors (age relative to the respiratory syncytial virus [RSV] season; household and/or maternal smoking; siblings and/or daycare attendance) and enables the cost-effective targeting of palivizumab to infants born at 32-35 weeks' gestational age (wGA) at greatest risk of related hospitalization (RSVH). This study provides the first evaluation of IRST-guided RSV prophylaxis in Colombia.
methodsThe IRST (with wGA substituted for chronological age as RSV is endemic in Colombia) plus other risk factors were assessed using data from 81 infants born 32-35 wGA with RSVH and 49 gestational- and age-matched controls. A cost-utility model comparing IRST-guided palivizumab versus no prophylaxis from the healthcare provider perspective was then adapted using Colombian costs and data (5% discounting). Infants could experience either RSVH, emergency room medically-attended, RSV infection, or remain uninfected/non-attended, with possible long-term respiratory morbidity up to 18 years of age over a lifetime time horizon.
resultsThe most predictive combination of risk factors was the IRST plus mixed breast and formula feeding and maternal education (area under the receiver operating characteristic curve = 0.823). For infants assessed at moderate- and high-risk of RSVH, the cost/quality-adjusted life year (QALY) was COP20,225,126 (USD4,752). Probabilistic sensitivity analyses resulted in a mean of COP22,193,734/QALY (USD5,214/QALY), with a 61.1% probability of palivizumab being cost-effective at a COP28,193,734 (USD6,624; 2022 gross domestic product/capita) willingness-to-pay threshold.
conclusionsPalivizumab prophylaxis of 32-35 wGA infants at moderate- and high-risk of RSVH, identified using the Colombian-adapted IRST, proved to be cost-effective versus no intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.